Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Androgen receptor-mediated pharmacogenomic expression quantitative trait loci: implications for breast cancer response to AR-targeting therapy.

Breast cancer research : BCR - 4 Jul 2024

Gao Huanyao, Wei Lixuan, Indulkar Shreya, Nguyen Thanh Thanh L, Liu Duan, Ho Ming-Fen, Zhang Cheng, Li Hu, Weinshilboum Richard M, Ingle James N, Wang Liewei

Abstract excerpt

BACKGROUND: Endocrine therapy is the most important treatment modality of breast cancer patients whose tumors express the estrogen receptor α (ERα). The androgen receptor (AR) is also expressed in the vast majority (80-90%) of ERα-positive tumors. AR-targeting drugs are not used in clinical practice, but have been evaluated in multiple trials and preclinical studies. METHODS: We performed a genome-wide study to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dihydrotestosterone

Share to Gene Expression Regulation, Neoplastic

Share to Nitriles

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Share to Receptors, Androgen

Source

Open in PubMed Open full text

Identifiers

PMID: 38965614
DOI: 10.1186/s13058-024-01861-2
PMCID: PMC11225427

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Androgen receptor-mediated pharmacogenomic expression quantitative trait loci: implications for breast cancer response to AR-targeting therapy.PMID 38965614Read ↗

Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profilingSemantic proximity Read ↗

In-silico identification and functional validation of allele-dependent AR enhancers.Semantic proximity Read ↗

The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast CancerSemantic proximity Read ↗

Characterizing steroid hormone receptor chromatin binding landscapes in male and female breast cancerSemantic proximity Read ↗

The androgen receptor interacts with GATA3 to transcriptionally regulate a luminal epithelial cell phenotype in breast cancer.Semantic proximity Read ↗

The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.Semantic proximity Read ↗

Pharmacogenomics of third-generation aromatase inhibitors.Semantic proximity Read ↗

Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy.Semantic proximity Read ↗

Pharmacogenomics of endocrine therapy in breast cancer.Semantic proximity Read ↗

Genetic prediction of long-term effects of aromatase inhibition on cancer and non-neoplastic disease riskSemantic proximity Read ↗

Variable expression quantitative trait loci analysis of breast cancer risk variantsSemantic proximity Read ↗

Androgen Receptor driven gene score identifies tumors with Epithelial to Mesenchymal Transition features in triple negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.